Skip to NavigationSkip to content

Early promise from Novavax's vaccine candidate for COVID-19

Published on 07/08/20 at 12:41pm

New Phase 1/2 on Novavax’s COVID-19 vaccine candidate NVX‑CoV2373 has shown that the therapy generated “robust antibody responses” when used with or without the company’s Matrix‑M adjuvant.

The study examined 131 healthy participants aged 18-59 years old. Antibody activity produced by the vaccine was observed as “numerically superior” to that seen in human convalescent sera, with all trial participants developing anti-spike IgG antibodies following initial dosing.

Furthermore, many participants also generated wild-type virus neutralising antibodies, with both these kinds of responses stacking up favourably against responses seen in patients hospitalised with COVID-19.

While only some participants generated wild-type virus neutralizing antibodies following a single dose, 100% generated such a response after receiving a second dose of the vaccine. IgC antibody activity was also shown to correlate strongly with neutralisation titers, illustrating that a “significant proportion” of the antibodies generated would be capable of mounting an effective immune response.  

“The Phase 1 data demonstrate that NVX-CoV2373 with our Matrix-M adjuvant is a well‑tolerated COVID-19 vaccine with a robust immunogenicity profile,” explained Dr Gregory Glenn, President of Research and Development at Novavax. “Using a stringent wild-type virus assay performed by investigators at the University of Maryland School of Medicine, NVX‑CoV2373 elicited neutralising antibody titres greater than those observed in a pool of COVID‑19 patients with clinically significant disease.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches